Potential role of interleukin 28B-gene polymorphism and natural immune enhancer treatment response in chronic HCV patients

Authors

  • Mohamed Y. Nasr Department of Biochemistry UPM
  • Alaa R. Hameed
  • Gamal Badra
  • Ibrahim H. El Sayed
  • Zaki Sheir

DOI:

https://doi.org/10.54987/jobimb.v3i1.230

Abstract

HCV infection is a major health problem in Egypt. Studies using safe natural products Blue green® tablet showed its antiviral effect. Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with HCV. The rationale of the present study is to evaluate the potential role of interleukin 28B gene polymorphism (IL28B) and natural immune
enhancer treatment response in chronic HCV patients. This study included 100 chronic HCV patients. Patients were classified into two groups: Group I, fifty patients with cirrhosis and advanced liver disease. Patients were unfit INF/ Ribavirin: Group II, fifty patients who refused INF/Ribavirin. Patients were treated with combination of natural products of Blue green® tablet (4 tablets daily which equivalent to 100 mg AFA/30 kg BW), vitamin D, tea spoon field paste of black seeds, olive oil and honey. Alanine Aminotransferase (AST), Aspartate Aminotransferase (ALT), complete blood count (CBC) were measured in the two groups. Detection of HCV-RNA level by quantitative PCR was done before & after 3, 6, 12 and 18 months of treatment. Genomic DNA extracted from all the 100 patient’s blood samples was analyzed for the rs12979860 SNP
of IL28B using a real-time polymerase chain technique incorporating SYBR Green. The results showed that, the activities of hepatic marker enzymes (AST and ALT), complete blood pictures (Hb, WBCs and Platelets), HCV RNA PCR, IL 28-B gene polymorphism were non-significantly (p>0.05) differences when compared untreated patients (Group I) and treated patients (Group )
were CC genotype before treatment was 8 (34%) & was 13 (26%) after treatment, CT genotype before treatment was 26 (52%) & was 28 (56%) after treatment, TT genotype before treatment was 7 (14%) & was 9 (18%) after treatment. Also, there were non-significant (p>0.05) differences between responder & non-responder in treated patients. In conclusion, the treatment
with natural immune enhancer in chronic HCV patients showed no significance correlation with IL 28 gene polymorphism

References

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52.

Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science. 2001;292(5525):2323–5.

Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, et al. Genetic history of hepatitis C virus in east Asia. J Virol. 2009;83(2):1071–82.

Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol. 2004;85(11):3173–88.

Cammà C, Di Bona D, Schepis F, Heathcote J, Zeuzem S, Pockros PJ, et al. Effect of Peginterferon Alfa-2a on liver histology in chronic hepatitis C: A Meta-analysis of Individual Patient Data. Hepatology. 2004;39(2):333–42.

Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don’t yet know. Hepatology. 2008;47(4):1371–83.

Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012;55(3):720–9.

Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012;12.

Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471–8.

Bouillon R, Carmeliet G, Verlinden L, Van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76.

Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina A-R, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;17(47):5184–90.

Jeong HJ, Ryu YB, Park S-J, Kim JH, Kwon H-J, Kim JH, et al. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009;17(19):6816–23.

Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343–8.

Wang H, Ding Y, Zhou J, Sun X, Wang S. The in vitro and in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3. Phytomedicine. 2009;16(2-3):146–55.

Tariq M. Nigella sativa seeds: Folklore treatment in modern day medicine. Saudi J Gastroenterol. 2008;14(3):105–6.

Irmisch G, Hoeppner J, Thome J, Richter J, Fernow A, Reisinger EC, et al. Serum fatty acids, antioxidants, and treatment response in hepatitis C infection: Greater polyunsaturated fatty acid and antioxidant levels in hepatitis C responders. J Clin Lipidol. 2011;5(4):288–93.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis c and treatment failure: A genome-wide association study. Gastroenterology. 2010;138(4):1338–45.e7.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011;53(3):746–54.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821–7.e1.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho Ã, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51(7):788–95.

Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24(8):F23–9.

Sambrook J, Fritsch EF, Maniatis T. Molecular cloning : a laboratory manual [Internet]. 2nd ed. Cold Spring Harbor Laboratory Press; 1989 [cited 2015 Oct 12]. Available from: http://trove.nla.gov.au/work/13615226?q&sort=holdings+desc&_=1444669266265&versionId=180145381

Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(SUPPL. 1):74–81.

Martinot-Peignoux M, Maylin S, Moucari R, Ripault M-P, Boyer N, Cardoso A-C, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther. 2009;14(4):501–11.

Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(SUPPL. 1):68–77.

Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, et al. Effectiveness of hepatitis c treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology. 2010;51(4):1137–43.

Takeshita M, Ishida Y-I, Akamatsu E, Ohmori Y, Sudoh M, Oto H, et al. Proanthocyanidin from Blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem. 2009;284(32):21165–76.

Jensen GS, Ginsberg DI, Huerta P, Citton M, Drapeau C. Consumption of Aphanizomenon flos-aquae has rapid effects on the circulation and function of immune cells in humans- A novel approach to nutritional mobilization of the immune system. The. J Am Nutraceutical Assoc. 2000;2:50–8.

Gilroy DJ, Kauffman KW, Hall RA, Huang X, Chu FS. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environ Health Perspect. 2000;108(5):435–9.

Eisenbrand G. Microcystins in algae products used as food supplements. Mol Nutr Food Res. 2008;52(6):735–6.

Baicuş C, Tanasescu C. Chronic viral hepatitis, the treatment with spiruline for one month has no effect on the aminotransferases. Romanian J Intern Med Rev Roum Médecine Interne. 2002;40(1-4):89–94.

Boyd MR. The NCI in vitro anticancer drug discovery screen. Anticancer Drug Dev Guide Preclin Screen Clin Trials Approv. 1997;23–42.

Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem. 2006;281(35):25177–83.

Schaeffer DJ, Krylov VS. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf. 2000;45(3):208–27.

Hayashi K, Hayashi T, Kojima I. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: In vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses. 1996;12(15):1463–71.

Jensen GS, Hart AN, Zaske LAM, Drapeau C, Gupta N, Schaeffer DJ, et al. Mobilization of human CD34+CD133+ and CD34+CD133- stem cells in vivo by consumption of an extract from Aphanizomenon flos-aquae-related to modulation of CXCR4 expression by an L-selectin ligand? Cardiovasc Revasc Med. 2007;8(3):189–202.

Kalantari H, Shahshahan Z, Hejazi SM, Ghafghazi T, Sebghatolahi V. Effects of silybum marianum on patients with chronic hepatitis C. J Res Med Sci. 2011;16(3):287–90.

Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study. Jpn J Cancer Res. 1999;90(4):367–71.

Lee YS, Yoon SK, Chung ES, Bae SH, Choi JY, Han JY, et al. The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J Korean Med Sci. 2001;16(5):585–91.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009;50(5):1360–9.

Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol. 1994;21(1):12–7.

Carreño V. Review article: Management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther. 2014;39(2):148–62.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology. 2006;130(4):1086–97.

Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol. 2011;55(3):692–701.

Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies. Am J Gastroenterol. 2011;106(1):38–45.

De Nicola S, Aghemo A, Grazia Rumi M, Galmozzi E, Valenti L, Soffredini R, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012;55(2):336–42.

Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int. 2013;7(2):533–8.

El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, El Din NGB, Zayed N, et al. Association of il28b snp with progression of egyptian hcv genotype 4 patients to end stage liver disease. Hepat Mon. 2012;12(4):271–7.

Downloads

Published

30.10.2015

How to Cite

Nasr, M. Y., Hameed, A. R., Badra, G., El Sayed, I. H., & Sheir, Z. (2015). Potential role of interleukin 28B-gene polymorphism and natural immune enhancer treatment response in chronic HCV patients. Journal of Biochemistry, Microbiology and Biotechnology, 3(1), 15–20. https://doi.org/10.54987/jobimb.v3i1.230

Issue

Vol. 3 No. 1 (2015)

Section

Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).